Contineum Therapeutics (CTNM) investor relations material

Company overview and clinical development

• Focus on neuroscience, inflammation, and immunology with two clinical-stage assets and multiple near-term readouts expected.

• PIPE-791 is a wholly owned, first-in-class brain-penetrant LPA-1 receptor inhibitor advancing in IPF, with phase 2 proof-of-concept study initiation planned before year-end.

• PIPE-307, a selective M1 receptor inhibitor, is in phase 2 studies for relapsing-remitting MS and MDD, in collaboration with Johnson & Johnson.

• Cash runway extends through the end of 2027, supporting execution of key milestones.

PIPE-791: Mechanism, differentiation, and clinical plans

• LPA-1 receptor activation drives fibrosis in IPF; prior BMS compounds showed efficacy but had off-target toxicity and dosing issues.

• PIPE-791 offers a unique pharmacokinetic profile with extended receptor coverage, QD dosing, and high selectivity, aiming to mitigate safety concerns seen with competitors.

• Phase 1B PET receptor occupancy data to be released soon; exploratory pain study in osteoarthritis and chronic back pain ongoing.

• IPF phase 2 trial design ensures comparability with BMS studies, focusing on maximizing target engagement and minimizing hypotension risk.

• Postponed initiation of PIPE-791 in progressive MS and CTX-343 to prioritize IPF study; both remain budgeted.

PIPE-307: MS and MDD programs and partnership

• M1 antagonism targets remyelination in MS, addressing a key unmet need beyond immune modulation.

• VISTA study in relapsing-remitting MS to read out in Q4, with primary endpoint on low contrast letter acuity and multiple exploratory endpoints.

• J&J collaboration includes shared development, with potential for increased royalties if co-funding registration studies.

• MDD program leverages rapid-acting antidepressant potential, with J&J running a four-week study targeting fast MADRS improvement.